Research On The Disclosure Problems And Countermeasures Of Key Audit Matters In X Pharmaceutical Manufacturing Enterprises

With the rapid development of China’s market economy and the increasing complexity of capital market,investors’ demand for the "quality" and "quantity" of audit reports is also increasing.The traditional audit report was only a brief and concise audit opinion issued by the certified public accountant to reflect the audit result,and investors have relatively limited access to corporate information.In the foregoing,in 2016,the Ministry of Finance of the People’s Republic of China revised and added a new standard No.1504,namely the China Certified Public Accountants Auditing Standard No.1504Communicating Key Audit Matters in Audit Reports(hereinafter referred to as"Standard No.1504"),which clearly stipulates that certified public accountants are required to add key audit matters paragraphs to the audit report.Standard No.1504 was fully implemented on 1 January 2018 for all listed companies.This paper chooses to study the disclosure of key audit matters of pharmaceutical manufacturing enterprises.By combining literature analysis method with case study method,this paper firstly expounds the research background,purpose and significance,content and methods of key audit matters,and summarizes existing viewpoints on key audit matters.Secondly,it expounds the industry characteristics of pharmaceutical manufacturing enterprises and describes the financial risk points and key audit areas of pharmaceutical manufacturing enterprises from the perspective of industry characteristics.It also makes a statistical analysis of the key audit matters disclosed by the listed companies on the Science and technology innovation board in the same industry from 2019 to 2021 from the three aspects of quantity,content and form.This paper analyzes and summarizes the relevant factors related to the disclosure of key audit matters of pharmaceutical manufacturing companies.Furthermore,it makes a statistical analysis on the disclosure of key audit items of X pharmaceutical manufacturing enterprise,introduces in detail the decision-making process of determining key audit items of X pharmaceutical manufacturing enterprise,sorts out the role of each responsible subject in the disclosure process of key audit items of X pharmaceutical manufacturing enterprise,summarizes the disclosure problems of key audit items of X pharmaceutical manufacturing enterprise,and puts forward countermeasures and suggestions.On the one hand,the research of this paper can standardize and optimize the information disclosure of key audit items of X pharmaceutical manufacturing enterprises;on the other hand,it also promotes other scholars to jointly discuss the information disclosure of key audit items of listed pharmaceutical manufacturing companies,so as to maximize the value of audit reports of listed pharmaceutical manufacturing companies.